These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 14968816)

  • 21. Lymphocyte gene therapy.
    Culver KW; Anderson WF; Blaese RM
    Hum Gene Ther; 1991; 2(2):107-9. PubMed ID: 1911929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy for genetic diseases.
    Anderson WF
    Hum Gene Ther; 1994 Mar; 5(3):281-2. PubMed ID: 8018743
    [No Abstract]   [Full Text] [Related]  

  • 23. Gene therapy. Patent award stirs a controversy.
    Nowak R
    Science; 1995 Mar; 267(5206):1899. PubMed ID: 7701313
    [No Abstract]   [Full Text] [Related]  

  • 24. [Severe combined immunodeficiency diseases].
    Tsuchiya S
    Nihon Rinsho; 2005 May; 63 Suppl 5():565-9. PubMed ID: 15954410
    [No Abstract]   [Full Text] [Related]  

  • 25. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
    Ramsey WJ; Mullen CA; Blaese RM
    Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of gene therapy for SCID is being confirmed.
    Cavazzana-Calvo M; Fischer A
    Lancet; 2004 Dec 18-31; 364(9452):2155-6. PubMed ID: 15610783
    [No Abstract]   [Full Text] [Related]  

  • 27. LMO2 and gene therapy for severe combined immunodeficiency.
    Stone BD
    N Engl J Med; 2004 Jun; 350(24):2526-7; author reply 2526-7. PubMed ID: 15195349
    [No Abstract]   [Full Text] [Related]  

  • 28. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
    Hershfield MS; Chaffee S; Sorensen RU
    Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Adenosine deaminase deficiency].
    Sakiyama Y
    Ryoikibetsu Shokogun Shirizu; 2000; (32):32-4. PubMed ID: 11212730
    [No Abstract]   [Full Text] [Related]  

  • 30. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
    Blaese RM
    Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy.
    Culver KW
    J Insur Med; 1996; 28(2):121-4. PubMed ID: 10163946
    [No Abstract]   [Full Text] [Related]  

  • 32. Gene therapy for severe combined immune deficiency poised for European approval: If green-lighted, Strimvelis would provide additional treatment option for second most common form of disease.
    Am J Med Genet A; 2016 Aug; 170(8):1955-6. PubMed ID: 27410196
    [No Abstract]   [Full Text] [Related]  

  • 33. Gene therapy for inherited immunodeficiency.
    Touzot F; Hacein-Bey-Abina S; Fischer A; Cavazzana M
    Expert Opin Biol Ther; 2014 Jun; 14(6):789-98. PubMed ID: 24823313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency.
    Hershfield MS
    Hum Mutat; 1995; 5(2):107-12. PubMed ID: 7749407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Severe combined immunodeficiencies: a case of adenosine-deaminase deficit].
    Macellaro P; Savarino A; Cucchi G; Lazzati A; Zuccotti GV
    Pediatr Med Chir; 2004; 26(3):191-5. PubMed ID: 16366403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene transfer therapy for heritable disease: cell and expression targeting.
    Mitani K; Clemens PR; Moseley AB; Caskey CT
    Philos Trans R Soc Lond B Biol Sci; 1993 Feb; 339(1288):217-24. PubMed ID: 8097051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adenosine deaminase deficiency].
    Okawa H
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):240-2. PubMed ID: 9833480
    [No Abstract]   [Full Text] [Related]  

  • 38. Perspectives on Manufacturing of High-Quality Cell Therapies.
    Rivière I; Roy K
    Mol Ther; 2017 May; 25(5):1067-1068. PubMed ID: 28462818
    [No Abstract]   [Full Text] [Related]  

  • 39. Ten years of gene therapy for primary immune deficiencies.
    Aiuti A; Roncarolo MG
    Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Looking into a Crystal Ball: An Interview with Ron Crystal.
    Davies K
    Hum Gene Ther Clin Dev; 2019 Sep; 30(3):97-101. PubMed ID: 31535944
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.